A further drug prioritised in the November 2018 NHS England prioritisation round has received approval for routine commissioning. The latest announcement, in the Specialised Commissioning Bulletin, discusses everolimus, designed to treat epileptic seizures caused by tuberous sclerosis complex. NHS England say:
“More than 300 people, mostly children, will benefit from this new treatment that reduces the number and severity of seizures, allowing children and adults with the condition to live a more normal life.”
The full report on the November prioritisation round is available here. Funding availability for everolimus is due to begin on 1st April 2019.